A cancer blood test is not a single test — it is a category that includes everything from a routine complete blood count to circulating tumor DNA analysis that can detect cancer signals before a tumor is visible on imaging. Blood tests play three distinct roles in oncology: raising clinical suspicion that warrants further workup, supporting diagnosis alongside imaging and biopsy findings, and monitoring cancer treatment response or detecting recurrence.
What blood tests cannot do is equally important to understand. No cancer blood test alone diagnoses cancer. Every cancer diagnosis requires tissue confirmation — a biopsy. And a normal cancer blood test panel does not mean cancer is absent; most early-stage cancers produce no detectable blood abnormalities. For a broader overview of what to expect when cancer is being investigated, see our guide to the cancer checkup appointment.
What a Cancer Blood Test Can and Cannot Do
The phrase “cancer blood test” covers at least seven distinct categories of tests. Understanding which type is being discussed — and what it is designed to detect — is essential for interpreting results without unnecessary alarm or false reassurance.
Three roles of cancer blood tests:
- Detection and screening signals. Tests that raise clinical suspicion — unexplained iron deficiency anemia on CBC prompting colorectal cancer evaluation, or an elevated PSA prompting prostate cancer workup.
- Diagnostic workup support. Tests ordered when cancer is already suspected — to characterize cancer type or narrow the differential diagnosis. Examples: SPEP and free light chains when multiple myeloma is suspected; AFP and beta-hCG when a testicular mass is found.
- Treatment monitoring and recurrence detection. Serial measurements of tumor markers or circulating tumor DNA (ctDNA) after treatment to assess response, detect residual disease, or identify early recurrence before imaging.
Routine Panels — What Standard Blood Work Reveals
Standard blood panels ordered at a routine physical are not explicitly cancer blood tests — but several findings carry direct cancer relevance.
Complete Blood Count (CBC)
White blood cell count (WBC): Markedly elevated WBC — particularly with an abnormal differential showing immature or malformed cells — is the hallmark laboratory finding of leukemia. Very low WBC can reflect bone marrow infiltration by tumor cells.
Hemoglobin and RBC: Unexplained iron deficiency anemia in any adult — particularly men at any age and postmenopausal women — warrants evaluation for colorectal cancer, which can cause chronic occult GI blood loss. Anemia of chronic disease is common in many advanced cancers.
Platelets: Thrombocytosis (elevated) occurs with some solid tumors through inflammatory mechanisms. Thrombocytopenia (low) can reflect bone marrow infiltration or treatment-induced suppression.
Peripheral blood smear: Identifies blasts (immature leukemia cells), atypical lymphocytes, or other morphological abnormalities not captured by automated counters — ordered when leukemia or lymphoma is clinically suspected.
Comprehensive Metabolic Panel (CMP)
Liver enzymes (ALT, AST, ALP, bilirubin): Elevated alkaline phosphatase and bilirubin suggest hepatic involvement from metastatic disease, primary liver cancer, or biliary obstruction (pancreatic cancer, cholangiocarcinoma). ALP elevation also occurs with osteoblastic bone metastases from prostate and breast cancer.
Calcium: Hypercalcemia is associated with multiple myeloma (from osteolytic bone destruction), bone metastases, and PTHrP-secreting paraneoplastic tumors — most classically squamous cell lung cancer. It is the most common electrolyte abnormality in cancer patients overall.
Albumin: Low albumin reflects malnutrition, hepatic involvement, or cancer cachexia — and is a negative prognostic marker across multiple cancer types.
LDH, ESR, and Non-Specific Markers
Lactate dehydrogenase (LDH): A non-specific marker of cell death and metabolic activity. Significantly elevated in lymphoma (reflecting tumor burden), testicular cancer, and melanoma. Used as a prognostic marker in several cancer types including the International Staging System for multiple myeloma.
ESR: Significantly elevated in Hodgkin’s lymphoma and multiple myeloma, but non-specific — elevated in infections and autoimmune conditions as well.
Uric acid: Monitored before chemotherapy for leukemia and lymphoma to prevent tumor lysis syndrome from rapid cancer cell destruction.
Cancer Blood Test — Tumor Markers
A tumor marker cancer blood test measures proteins, hormones, or other molecules produced at higher levels by cancer cells or by the body in response to cancer. This is one of the most ordered — and most misunderstood — categories of cancer blood test.
| Tumor Marker | Primary Cancer | Non-Cancer Elevations | Used For |
|---|---|---|---|
| PSA | Prostate | BPH, prostatitis, urologic procedures | Screening (shared decision-making); post-treatment monitoring |
| CA-125 | Ovarian | Endometriosis, fibroids, PID, pregnancy, liver disease | Diagnosis + monitoring (not general screening) |
| CEA | Colorectal | Smoking, COPD, IBD, liver disease | CRC surveillance post-treatment; lung, breast, gastric monitoring |
| AFP | Liver (HCC), testicular (NSGCT) | Liver disease, cirrhosis, hepatitis, pregnancy | HCC surveillance in high-risk; testicular cancer diagnosis/monitoring |
| Beta-hCG | Testicular (NSGCT), gestational trophoblastic | Normal pregnancy | Testicular cancer diagnosis/monitoring |
| CA 19-9 | Pancreatic, cholangiocarcinoma | Cholestasis, IBD, liver disease | Pancreatic cancer monitoring (not screening) |
| CA 15-3 / CA 27-29 | Breast | Benign breast disease, liver disease | Breast cancer post-treatment monitoring |
| Thyroglobulin | Thyroid (differentiated) | Only meaningful post-thyroidectomy | Post-thyroidectomy surveillance for recurrence |
| Calcitonin | Medullary thyroid | Renal failure, autoimmune thyroiditis | MTC diagnosis and monitoring |
| NSE | Small cell lung, neuroendocrine | Hemolysis (pre-analytical artifact) | SCLC and neuroendocrine tumor monitoring |
| Chromogranin A | Neuroendocrine tumors | PPI use, renal failure | NET monitoring |
Hematologic and Protein Blood Tests for Blood Cancers
Blood cancers — leukemia, lymphoma, and multiple myeloma — have specific blood-based markers that are more diagnostic than routine panels.
SPEP and Free Light Chains (Multiple Myeloma)
Serum Protein Electrophoresis (SPEP): Separates serum proteins by electrical charge. An M-spike (monoclonal protein peak) is the hallmark finding of multiple myeloma, MGUS, and Waldenström macroglobulinemia. A detected M-protein triggers reflex immunofixation and urine UPEP (Bence Jones proteins).
Free light chains (kappa/lambda ratio): Highly sensitive for plasma cell disorders. Combined with SPEP, sensitivity for multiple myeloma approaches 99%. Critical for monitoring non-secretory myeloma where no M-protein is produced.
Beta-2 microglobulin: A component of the Revised International Staging System (R-ISS) for myeloma — elevated levels indicate worse prognosis. Also elevated in lymphoma and some leukemias.
Flow Cytometry / Immunophenotyping
Flow cytometry identifies cancer cells in blood or bone marrow by surface proteins (antigens) they express — classifying cell lineage (B-cell, T-cell, or myeloid), maturation stage (mature vs. blast), and abnormal antigen co-expression patterns that distinguish malignant from reactive cells. Used to diagnose CLL, acute leukemia, and lymphoma involvement in peripheral blood.
Molecular and Genetic Blood Tests
BCR-ABL PCR (CML): The Philadelphia chromosome translocation (9;22) creates the BCR-ABL fusion gene that drives chronic myelogenous leukemia. Quantitative PCR measures BCR-ABL transcript levels for diagnosis and treatment monitoring. A major molecular response (BCR-ABL ≤0.1% on the international scale) is a key milestone with tyrosine kinase inhibitor therapy.
JAK2 V617F mutation: Present in ~95% of polycythemia vera and ~50% of essential thrombocythemia and primary myelofibrosis. First-line test in the myeloproliferative neoplasm workup.
Liquid Biopsy Cancer Blood Test — Circulating Tumor DNA (ctDNA)
Liquid biopsy is among the fastest-evolving areas in cancer blood testing. The term refers to detection of cancer-derived material — most commonly circulating tumor DNA (ctDNA) — in the bloodstream without a tissue biopsy.
Cancer cells shed DNA fragments into the blood as they die. These tumor-derived fragments can be detected by sensitive next-generation sequencing techniques in a simple blood draw. The fraction of total cell-free DNA that is tumor-derived is typically very low (0.01–1%), requiring high-sensitivity assays.
Four clinical applications of ctDNA:
- Mutation profiling when tissue is unavailable. FDA-cleared tests (Guardant360 CDx, FoundationOne Liquid CDx) identify actionable mutations — EGFR in lung cancer, KRAS/BRAF in colorectal cancer, PIK3CA in breast cancer, BRCA1/2 in ovarian cancer — to guide targeted therapy selection.
- Treatment response monitoring. Falling ctDNA levels after starting therapy indicate cancer cell death. Rising ctDNA can predict disease progression weeks before imaging shows it.
- Minimal residual disease (MRD) detection after surgery. Patients with detectable ctDNA after curative-intent colorectal cancer surgery have approximately 10 times the recurrence risk of ctDNA-negative patients (CIRCULATE-Japan data).
- Early detection (investigational). Detecting cancer signals before symptoms or imaging — the basis of multi-cancer early detection tests covered in the next section.
Multi-Cancer Early Detection (MCED) Blood Tests
Multi-cancer early detection tests attempt to use a single cancer blood test to screen for dozens of cancer types simultaneously. They are the most discussed — and most easily misunderstood — development in this field.
Galleri (GRAIL) analyzes DNA methylation patterns in cell-free blood DNA. Different cancer types have characteristic methylation “signatures” that can suggest tissue of origin. Galleri claims detection signals for 50+ cancer types.
The PATHFINDER study (Lancet 2023) tested Galleri in 6,621 adults aged 50+: 1.4% had a cancer signal detected; positive predictive value was approximately 38% — meaning that for every 100 people with a positive result, about 62 did not have cancer on confirmatory workup. Sensitivity for cancer types lacking existing screening options was 51.5%.
When Specific Cancer Blood Tests Are Ordered
| Clinical Scenario | Blood Test(s) Ordered |
|---|---|
| Unexplained fatigue, anemia | CBC, reticulocyte count, iron studies, CMP |
| Suspected leukemia | CBC with differential + peripheral smear; flow cytometry |
| Suspected lymphoma | CBC, LDH, ESR, CMP; tissue biopsy required for diagnosis |
| Suspected multiple myeloma | CBC, CMP (calcium, creatinine), SPEP, free light chains, beta-2 microglobulin, LDH |
| PSA screening discussion (men 55–69) | PSA; possibly free/total PSA ratio if elevated |
| CRC surveillance post-treatment | CEA every 3–6 months × 2 years |
| Ovarian cancer workup | CA-125, HE4 (ROMA score); pelvic ultrasound |
| HCC surveillance (cirrhosis/HBV) | AFP every 6 months; abdominal ultrasound |
| Testicular mass | AFP, beta-hCG, LDH |
| Thyroid cancer follow-up (post-thyroidectomy) | Thyroglobulin, anti-thyroglobulin antibodies |
| Hypercalcemia workup (myeloma concern) | Calcium, SPEP, free light chains, PTH |
| CML diagnosis/monitoring | BCR-ABL quantitative PCR |
| MPN workup (elevated RBC, platelets) | JAK2 V617F mutation; CBC with differential |
| Mutation profiling for targeted therapy | ctDNA liquid biopsy (Guardant360 CDx or FoundationOne Liquid CDx) |
What to Do If a Cancer Blood Test Is Abnormal
An abnormal cancer blood test result almost never means a same-day diagnosis. The next step is almost always more information — additional blood tests, imaging, specialist referral, or repeat testing to assess whether the abnormality is stable or changing.
Tumor markers in particular have a high false-positive rate in the general population. A single elevated CEA, CA-125, or PSA in an otherwise asymptomatic patient usually triggers repeat testing or imaging before clinical action is taken. The trend over time (rising vs. stable vs. falling) matters more than a single value.
Ask your provider three questions when a result is abnormal:
- “What is this result most likely to represent — and what is the most serious possibility?”
- “What is the next step to clarify this finding?”
- “How long until we know more — and what symptoms should prompt me to call before then?”
If you’ve been referred for further workup after an abnormal blood test, our guide to what happens at a cancer checkup explains what to expect. If you’re also noticing symptoms, a cancer symptoms checklist organized by body system can help you communicate them clearly to your provider. Understanding your personal cancer risk can also help put blood test results in the right context.
Cancer Blood Test Quick Reference
| Test Category | What It Measures | Cancer Relevance | Key Limitation |
|---|---|---|---|
| CBC | Blood cell counts | Leukemia, lymphoma, anemia from CRC | Non-specific; many non-cancer causes |
| CMP | Organ chemistry | Liver mets, bone mets, myeloma (calcium) | Non-specific |
| LDH | Cell death/turnover | Lymphoma, testicular, melanoma burden | Very non-specific |
| Tumor markers | Cancer-associated proteins | Cancer-specific surveillance and monitoring | Many false positives; not general screening tools |
| SPEP + FLC | Serum proteins | Multiple myeloma, MGUS, Waldenström | Requires follow-up immunofixation |
| Flow cytometry | Cell surface antigens | CLL, acute leukemia, lymphoma | Requires hematology interpretation |
| ctDNA liquid biopsy | Tumor DNA in blood | Mutation profiling, MRD detection, monitoring | Low sensitivity for early-stage/low-burden cancer |
| MCED (Galleri) | cfDNA methylation patterns | Multi-cancer early detection (investigational) | Not FDA-approved; 38% PPV; not a replacement for established screening |
Frequently Asked Questions
What is a cancer blood test?
A cancer blood test is any blood-based test used in the detection, diagnosis, or monitoring of cancer. This includes routine panels (CBC, CMP) that may reveal cancer-related abnormalities, tumor marker tests that measure cancer-associated proteins, hematologic protein tests for blood cancers (SPEP, free light chains, flow cytometry), molecular tests (BCR-ABL PCR, JAK2), and newer liquid biopsy and multi-cancer early detection tests that analyze circulating tumor DNA or cell-free DNA methylation patterns. According to the National Cancer Institute, no single blood test can diagnose cancer — tissue biopsy remains required for confirmation.
Can a cancer blood test detect cancer early?
Some blood tests can detect signals that raise suspicion of early cancer — but no currently available cancer blood test reliably detects all cancers at early stages. Liquid biopsy tests (ctDNA) and multi-cancer early detection tests (Galleri, CancerSEEK) are designed for early detection but have significant limitations: sensitivity is lower for early-stage cancer when tumor burden and DNA shedding are low, and positive predictive value is modest. The Galleri MCED test in the PATHFINDER study had a PPV of approximately 38%. Established screening modalities — colonoscopy, mammography, LDCT, Pap smear — remain the standard of care for cancers where they exist. See our guide to preventive cancer screening for more on validated screening tools.
What does an abnormal cancer blood test mean?
An abnormal cancer blood test result requires further evaluation — it does not constitute a cancer diagnosis. The result may reflect a non-cancer cause (many tumor markers are elevated by benign conditions), or it may be the starting point for a workup (imaging, specialist referral, biopsy) that ultimately confirms or excludes cancer. In most cases, the next step after an abnormal cancer blood test is repeat testing, additional laboratory evaluation, or imaging — not immediate biopsy or treatment.
Which blood test detects cancer most accurately?
No single cancer blood test detects all cancers accurately. Accuracy depends on cancer type and clinical context. For specific blood cancers, certain tests are highly diagnostic: BCR-ABL PCR for CML, SPEP + free light chains for multiple myeloma (combined sensitivity >99%). For solid tumors, tumor markers have limited sensitivity and specificity when used alone. Liquid biopsy (ctDNA) is highly specific for known mutations in established cancers but less sensitive for early-stage disease. The most accurate cancer detection combines blood tests with imaging and, ultimately, tissue biopsy. For more on how these tests fit into a cancer diagnosis workup, see the ACS overview of cancer diagnostic tests.
What is a liquid biopsy cancer blood test?
A liquid biopsy is a cancer blood test that detects tumor-derived material — most commonly circulating tumor DNA (ctDNA) — in the bloodstream. Unlike a tissue biopsy that samples the tumor directly, a liquid biopsy samples the blood for DNA fragments shed by cancer cells. FDA-cleared liquid biopsy tests (Guardant360 CDx, FoundationOne Liquid CDx) are used to identify actionable mutations in patients with known solid tumors when tissue biopsy is unavailable, and to monitor treatment response. They are also under investigation for post-surgical minimal residual disease monitoring.
Do cancer blood tests require fasting?
Most cancer-specific blood tests — tumor markers, SPEP, free light chains, flow cytometry, ctDNA — do not require fasting. Routine CMP includes glucose and lipid values that may require fasting, but the cancer-relevant components (liver enzymes, calcium, creatinine) are not affected by fasting status. Your provider will specify if fasting is required for any portion of the blood draw.
How often should I get a cancer blood test?
There is no single recommended frequency for a “cancer blood test” because the category covers very different tests with different indications. Routine CBC and CMP are typically ordered annually at a complete physical. Tumor marker monitoring (CEA, PSA, CA-125) after cancer treatment is done every 3–6 months on a schedule determined by cancer type and treatment history. Multi-cancer early detection tests like Galleri are being studied with annual testing in research protocols, but no standard recommendation exists. Discuss specific intervals with your primary care provider or oncologist. See our guide to annual cancer screening for a full overview of age-based recommendations.
Sources & Further Reading
- NCI — Understanding Laboratory Tests in Cancer
- ACS — Tests Used to Detect and Diagnose Cancer
- USPSTF — Cancer Screening Recommendations
- Johansson et al. — PATHFINDER Study, Lancet 2023
- Lennon et al. — DETECT-A (CancerSEEK), Science 2020
- Kotani et al. — CIRCULATE-Japan ctDNA CRC Study, Nature Medicine 2023
- FDA — Guardant360 CDx and FoundationOne Liquid CDx approvals
- ASCO — Tumor Markers in Common Use (Clinical Practice Guideline)
This article is for educational purposes only and does not constitute medical advice. Blood test results should be interpreted by a qualified healthcare provider in the context of your full clinical picture.
Pingback: Tumor Markers: What They Are and What They Cannot Tell You - Horizon Health Guide
Pingback: Biopsy for Cancer: Types, What to Expect, and Results - Horizon Health Guide
Pingback: Imaging Tests for Cancer: CT, MRI, PET, and More - Horizon Health Guide
Pingback: Cancer Grade: What It Means and Why It Matters for Treatment - Horizon Health Guide